Safety profile of atomoxetine in the treatment
of children and adolescents with ADHD

by
Wernicke JF, Kratochvil CJ.
Eli Lilly and Company,
Lilly Corporate Center DC-6026,
Indianapolis, IN 46285, USA.
J Clin Psychiatry 2002;63 Suppl 12:50-5


ABSTRACT

Atomoxetine is a selective norepinephrine reuptake inhibitor that is being developed for the treatment of attention-deficit/hyperactivity disorder (ADHD). Atomoxetine will be the first nonstimulant medication approved by the U.S. Food and Drug Administration (FDA) for the treatment of ADHD. Throughout the testing phases, more than 2000 children and adolescents have been exposed to atomoxetine in clinical trials, with both the number of exposures and the length of exposure time increasing. Serious adverse events have not been clearly associated with the drug, and there have been few discontinuations due to adverse events. The most common drug-related event reported in trials has been decreased appetite and an initial period of weight loss followed by an apparently normal rate of weight gain. These events tend to appear early in the course of treatment with atomoxetine and then decline. Atomoxetine has also been associated with mild increases in blood pressure and pulse that plateau during treatment and resolve upon discontinuation. There have been no effects seen on the QT interval, and the cytochrome P450 2D6 metabolism of patients seems to have little effect on safety or tolerability of the drug. This article will review the data from completed and ongoing clinical trials available at the time the New Drug Application was submitted to the FDA. Described are serious adverse events, discontinuations, and treatment-emergent adverse events. Specifically, cardiac effects and effects on weight, height, and metabolism that are related to treatment of ADHD with atomoxetine in children and adolescents are discussed.


ADHD
Options
Noradrenaline
Drug companies
Tomoxetine and ADHD
Tomoxetine from Eli Lilly
Once-daily tomoxetine for ADHD
Big Pharma meets Madison Avenue
Ritalin, Adderall and Strattera for ADHD
Tomoxetine (Strattera) v methylphenidate (Ritalin)
Atomoxetine (Strattera): prescribing information (PDF)


Refs
and further reading

HOME
HedWeb
Nootropics
erythroxylum-coca.com
Future Opioids
BLTC Research
MDMA/Ecstasy
Superhapiness?
Utopian Surgery?
The Abolitionist Project
The Hedonistic Imperative
The Reproductive Revolution
Critique of Huxley's Brave New World

The Good Drug Guide
The Good Drug Guide

The Responsible Parent's Guide
To Healthy Mood Boosters For All The Family